Both (-) and (+)-naloxone attenuate inflammation-mediated neurodegeneration by inhibition of microglial activation through superoxide reduction in an opioid receptor-independent manner. Multiple lines of evidence have documented a pivotal role of overactivated NADPH oxidase (NOX2) in inflammation-mediated neurodegeneration. We hypothesized that NOX2 might be a novel action site of naloxone to mediate its anti-inflammatory actions.
Inhibition of NOX-2-derived superoxide by (-) and (+)-naloxone was measured in lipopolysaccharide (LPS)-treated midbrain neuron-glia cultures and phorbol myristate acetate (PMA)-stimulated neutrophil membranes by measuring the superoxide dismutase (SOD)-inhibitable reduction of tetrazolium salt (WST-1) or ferricytochrome c. Further, various ligand (3H-naloxone) binding assays were performed in wild type and gp91phox-/- neutrophils and transfected COS-7 and HEK293 cells. The translocation of cytosolic subunit p47phox to plasma membrane was assessed by western blot.
Both (-) and (+)-naloxone equally inhibited LPS- and PMA-induced superoxide production with an IC50 of 1.96 and 2.52 μM, respectively. Competitive binding of 3H-naloxone with cold (-) and (+)-naloxone in microglia showed equal potency with an IC50 of 2.73 and 1.57 μM, respectively. 3H-Naloxone binding was elevated in COS-7 and HEK293 cells transfected with gp91phox; in contrast, reduced 3H-naloxone binding was found in neutrophils deficient in gp91phoxor in the presence of a NOX2 inhibitor. The specificity and an increase in binding capacity of 3H-naloxone were further demonstrated by 1) an immunoprecipitation study using gp91phoxantibody, and 2) activation of NOX2 by PMA. Finally, western blot studies showed that naloxone suppressed translocation of the cytosolic subunit p47phoxto the membrane, leading to NOX2 inactivation.
Strong evidence is provided indicating that NOX2 is a non-opioid novel binding site for naloxone, which is critical in mediating its inhibitory effect on microglia overactivation and superoxide production.
Recent studies strongly support that neuroinflammation plays a critical role in the pathogenesis of various neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis, Huntington's disease and multiple system atrophy . Microglia, the resident immune cells of the brain, are the major players in the initiation of neuroinflammation and subsequent pathogenesis of neurodegeneration. Once activated, microglia produce and release a variety of proinflammatory factors, such as cytokines, chemokines and reactive free radicals, which contribute to the neurodegenerative process . Thus, anti-inflammatory therapy has been considered a new strategy for disease-modifying intervention.
In the course of developing new anti-inflammatory drugs for PD, we discovered that naloxone, a commonly used antagonist of opioid receptors, was highly effective in preventing dopaminergic neurodegeneration in different rodent PD models by inhibiting inflammatory responses [3–6]. The inhibitory effects of naloxone on inflammatory responses have been reported in our previous studies in vivo and in vitro. Systemic infusion of 1 mg/kg (+)- or (-)-naloxone significantly reduced intranigral LPS-induced microglial activation and neurotoxicity . In midbrain and cortical neuron-glia cultures, microglial activation and related proinflammatory cytokine production such as nitrite oxide, TNFα and IL-1β, in response to LPS stimulation, were also attenuated by naloxone at 0.1-1 micromolar concentrations [3, 4]. Further dose-response study showed a bimodal curve (effective in both micromolar and subpicomolar, but less effective in nanomolar concentrations) for both anti-inflammatory and neuroprotective effects of naloxone . Despite a huge concentration difference, mechanistic studies have revealed that inhibition of microglial superoxide production is the key event underlying naloxone-afforded neuroprotection for both micromolar and subpicomolar concentrations [3, 6, 7]. Furthermore, we have reported that the neuroprotective effect of naloxone is independent of opioid receptors, since (+)-naloxone, which is an inactive isomer in the activation of opioid receptors, exerts the same potency as the (-)-naloxone in neuroprotection [3–6]. Recent reports from several laboratories have also shown opioid receptor-independent actions of naloxone. Watkins' group reported that (+)-naltrexone, (+)-naloxone and (-)-naloxone, which they showed to be Toll-like receptor 4 (TLR4) antagonists in vitro on both stably transfected HEK293-TLR4 and microglial cell lines, suppress neuropathic pain with complete reversal upon chronic infusion [8, 9]. In a drug addiction study, Wang et al. demonstrated that the acute Gs coupling induced by morphine is completely prevented by co-treatment with both (-) and (+)-naloxone . Similarly, it has been reported that naloxone displays neuroprotective effects in a two-hit seizure model by reducing both cytokine production and microglial activation . Both (-) and (+)-naloxone have also been found to be capable of reducing the severity of aortic atherosclerosis in apolipoprotein-E (apo-E)-deficient mice through inhibition of macrophage activation and superoxide release . Taken together, the non-opioid actions of naloxone may have wide implications in therapy for a variety of diseases. Thus, it is critical to elucidate the novel non-opioid binding site(s) and action mechanisms of naloxone.
The major purpose of this study was to search for the potential site of action mediating the anti-inflammatory and neuroprotective effects of naloxone using a ligand (3H-naloxone) binding assay. We have initially attempted to determine both the low (micromloar) and high (subpicomolar) affinity sites of naloxone. However, the specific activity of 3H-naloxone is too low to study the binding at subpicomolar concentrations. Thus, the main effort of this study focused on the micromolar concentrations of naloxone. Here, for the first time, we report that gp91phox, the catalytic subunit of microglial NOX2, is a novel non-opioid binding site of naloxone. Binding of naloxone reduced the translocation of cytosolic subunits to the plasma membrane, leading to inhibition of NOX2 and related superoxide production, which is critical in mediating the anti-inflammatory and neuroprotective effects of naloxone.
[3H]-naloxone was purchased from Perkin Elmer Life Sciences (Boston, MA, USA). Cell culture reagents were obtained from Invitrogen Life Technologies (Grand Island, NY, USA). Rabbit anti-p47phoxwas purchased from Upstate (Billerica, MA, USA). FITC-conjugated goat anti-rabbit immunoglobulin G (IgG) was obtained from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Rabbit anti-β-actin was obtained from Sigma (St. Louis, MO, USA). Mouse anti-gp91phoxwas purchased from BD Transduction Laboratories (San Jose, CA, USA).
NOX2-deficient (gp91phox-/-) and wild type (WT) C57BL/6 J (gp91phox+/+) mice were obtained from the Jackson Laboratory. All animals were housed in a pathogen free facility with a 12-hour light/12-hour dark cycle and ad libitum access to food and water. Housing, breeding and experimental use of the animals were performed in strict accordance with the National Institutes of Health guidelines.
Primary mesencephalic neuron/glia culture
Briefly, dissociated cells were seeded at 1 × 105/well in poly-D-lysine coated 96-well plates. The cultures were maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air in minimum essential medium (MEM) containing 10% heat-inactivated fetal bovine serum (FBS), 10% heat-inactivated horse serum, 1 g/L glucose, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 μM nonessential amino acids, 50 U/ml penicillin, and 50 μg/ml streptomycin. Seven days later, cultures were used for drug treatments. At the time of treatment, immunocytochemical analysis indicated that the neuron-glia culture consisted of 10% microglia, 50% astrocytes, 40% neurons, and 1% tyrosine hydroxylase (TH)-immunoreactive neurons. For treatment, cultures were changed to treatment medium composed of MEM, 2% FBS, 2% HHS, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 U/ml penicillin, and 50 μg/ml streptomycin.
The production of superoxide was assessed by measuring the superoxide dismutase (SOD) -inhibitable reduction of the tetrazolium salt WST-1. Primary neuron/glia cultures in 96-well plates were washed twice with Hanks' balanced salt solution (HBSS) without phenol red. Cells were then incubated at 37°C for 30 minutes with vehicle control or (-) and (+)-naloxone in HBSS (50 μl/well). Subsequently, 50 μl of HBSS with and without SOD (50 U/ml) was added to each well along with 50 μl of WST-1 (1 mM) in HBSS and 50 μl of vehicle or LPS. The absorbance at 450 nm was read with a SpectraMax Plus microplate spectrophotometer (Molecular Devices) every 2 minutes for 30 minutes. The difference between the absorbances in the presence and absence of SOD was considered to be the amount of produced superoxide.
Preparation, activation, and fractionation of rat blood neutrophils and cell-free assay of NADPH-dependent superoxide production by PMA-stimulated neutrophils membranes.
Neutrophils were purified from fresh blood collected from the abdominal aorta of adult Fischer 344 male rats as described before . Briefly, heparinized blood was sedimented with dextran, and the neutrophils were isolated by centrifugation through the Ficoll-Hypaque density gradient, followed by a hypotonic lysis to remove residual erythrocytes. Purified neutrophils (> 95% viable cells, trypan blue exclusion) were resuspended in warmed phenol red-free HBSS (37°C) and stimulated for 15 minutes with 100 nM PMA or vehicle with gentle agitation. The reaction was stopped by the addition of ice-cold HBSS buffer. Pelleted cells were disrupted and fractionated at 4°C by discontinuous sucrose density gradient sedimentation as described before. Superoxide generation in membrane fractions was measured by monitoring the reduction of ferricytochrome c in a spectrophotometer with the water-jacketed cuvette compartment maintained at 37°C. The reaction was initiated by the addition of 0.2 mM (final concentration) freshly prepared NADPH (tetrasodium salt, Type I, Sigma) into 1.0-ml micro-cuvettes containing detection buffer (100 μM ferricytochrome c, 10 μM FAD, 2 mM MgCl2, 2 m NaNs, and 10 mM Hepes, pH 7.4) and 10 μg of membrane. (-) or (+)-Naloxone (a final concentration of 10 μM) or vehicle was added quickly to micro-cuvettes to determine the inhibition of superoxide production. The reference cuvette was supplemented with 600 U/ml SOD (Type I, 3000 U/mg protein, Sigma). Initial rates of superoxide production were calculated from the linear segment of the increase in absorbance at 550 nm and normalized to vehicle-treated control.
Xanthine/xanthine oxidase reaction
To determine whether naloxone acts as a superoxide scavenger, the superoxide-generating xanthine/xanthine oxidase system was used. Briefly, assays were performed in the presence of indicated concentrations of (-) and (+)-naloxone isomers, 0.01 U xanthine oxidase, 50 μM xanthine, 250 μM partially acetylated WST-1 in 50 mM potassium phosphate buffer (pH 7.6) in a 96-well plate (100 μL/well final volume). Xanthine was added to initiate the reaction, and absorbance at 450 nm was continuously monitored for 5 minutes using a Synergy HT multi-detection microplate reader (Bio-Tek Instruments, Winooski, VT, USA). Results are expressed as a percentage of the increase in absorbance per minute observed with xanthine oxidase only.
HEK293 cells were maintained in DMEM supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere of 5% CO2 and 95% air. One day before transfection, 1 × 106 HEK293 cells were seeded into 6-well plates. Flag-gp91phoxand Myc/His-p22phoxplasmids were cotransfected into HEK293 cells using Lipofectamine 2000 (Invitrogen Life Technologies, Grand Island, NY) according to the manufacture's protocol. After 48 hours of expression, cells were collected for binding experiments.
Isolation of neutrophils from peritoneal cavity
Inflammation was induced by injecting 1 ml of casein solution into the peritoneal cavity of gp91phox-/-and gp91phox+/+mice for overnight and repeat injection the next morning. Three hours after the second injection, mice were euthanized and 5 ml harvest solution (0.02% EDTA in PBS) was injected into the peritoneal cavity. All peritoneal fluids were transferred into 50 ml centrifuge tubes, and then centrifuged at 200 × g for 10 minutes. The pellets were washed three times using PBS, and then collected for use .
[3H]-naloxone binding assay
Binding experiments were performed according to the methods of Herren, Liu and Zhou [4, 15, 16]. Briefly, whole cell (2 × 106 or 4 × 106) or membrane (250 μg) from neutrophils, COS-7, HEK293 or BV2 microglia were incubated with [3H]-naloxone (6 nM) plus 10 μM unlabeled naloxone isomers in binding buffer (HBSS + 10% serum) for 2 hours at 4°C. Afterward, the buffer was removed and cells or membrane were washed three times with ice-cold HBSS using 1.0 μm pore size glass fiber filter (Whatman, Florham Park, NJ, USA). Then, cells or membranes were mixed with 10 ml of Ultima Gold scintillation fluid (PerkinElmer, Waltham, MA, USA) and counted for radioactivity. Experiments were performed in triplicate and results are expressed as percentage of total binding observed with corresponding WT group.
[3H]-naloxone immunoprecipitation binding
The 3H-naloxone immunoprecipitation binding study was performed by immunoprecipitation using anti-gp91phoxantibody (IP-binding). Specifically, we prepared plasma membranes from wild type COS-7 and COS-7-gp91phox-p22phox(COS-7 cells stably expressed with gp91phoxand p22phox). Membrane pellets were suspended in 0.5 ml IP buffer (10 mM HEPES (pH 7.4), 1% Triton X-100, 5 mM Mg2Cl, 10 mM KCl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM dithiothreitol (DTT), 10% glycerin and protease inhibitor cocktails). After pre-incubation with 3H-labeled naloxone (6 nM) in the presence of 10 μM unlabeled naloxone for 30 minutes, membrane aliquots (0.25 mg protein) were incubated overnight with the addition of control immunoglobulin G (IgG) or anti-gp91phoxpolyclonal antibody (Santa Cruz Biotech, Santa Cruz, CA) at 4°C. Immunoprecipitation was performed by protein A/G beads (Santa Cruz Biotech). After 4 hours incubation at 4°C, protein beads were washed three times by IP buffer. Then the beads were eluted twice by 0.5 ml glycine buffer (0.1 M at pH 2.5), and radioactivity was counted with a liquid scintillation counter. The binding capacity was determined by subtracting the binding of control IgG from that of gp91phoxantibody.
Membrane fractionation and western blot analysis
Membrane fractionations were extracted as described previously . BV2 microglia were lysed in hypotonic lysis buffer (1 mM Tris, 1 mM KCl, 1 mM ethylene glycol tetraacetic acid (EGTA), 1 mM ethylenediaminetetraacetic acid (EDTA), 0.1 mM DTT, 1 mM PMSF, and 10 μg/ml) cocktail protease inhibitor incubated on ice for 30 minutes and then subjected to Dounce homogenization (20-25 St, tight pestle A). The lysates were centrifuged at 1,600 × g for 15 minutes and the supernatant was centrifuged at 100,000 × g for 30 minutes. The pellets solubilized in 1% Nonidet P-40 hypotonic lysis buffer were used as membranous fraction. Equal amounts of protein were separated by 4% to 12% Bis-Tris Nu-PAGE gel and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked with 5% nonfat milk and incubated with rabbit anti-p47phoxand mouse anti-gp91phox(1/1,000 dilution) and HRP-linked anti-rabbit or mouse IgG (1/3000 dilution) for 2 hours. Enhanced chemiluminescence (ECL) reagents (Amersham Biosciences, Piscataway, NJ, USA) were used as a detection system.
The data were presented as the mean ± SE. For multiple comparisons of groups, analysis of variance (ANOVA) was used. Statistical significance between groups was assessed by paired or unpaired Student's t test, with Bonferroni's correction. A value of P < 0.05 was considered.
Naloxone inhibits superoxide production through inhibition of NOX2
Although naloxone has been reported to inhibit superoxide production, the detailed mechanism is not known. In the present study, we first demonstrated that superoxide production induced by LPS was significantly inhibited by (-) and (+)-naloxone isomers in a dose-dependent manner with a half maximal inhibitory concentration (IC50) of 1.96 and 2.52 μM, respectively (Figure 1A). These values are much higher than the IC50 for the binding of opioid receptors (in nanomolar), but they are in similar ranges to those previously reported for inhibiting superoxide production in neutrophils . These results also support the contention that naloxone inhibition of superoxide is independent of opioid receptors. Our previous reports indicate that naloxone in these micromolar concentrations was not toxic to cell cultures and no obvious toxic signs were observed in animal studies with a 10 mg/kg/day dosage [3–6]. To rule out the possibility that the reduction of LPS-induced superoxide release was attributed to the superoxide scavenging capacity of naloxone, we evaluated the effect of various concentrations of (-) and (+)-naloxone on superoxide production using the xanthine/xanthine oxidase superoxide-generating system. The increased level of superoxide by the xanthine/xanthine oxidase system was largely inhibited in the presence of SOD (Figure 1), but not by both (-) and (+)-naloxone (0.01 to 100 μM) (Figure 1B), indicating that the naloxone inhibited LPS-induced increase of superoxide from microglia was not due to the superoxide scavenging capacity. Since NOX2 is a major superoxide-generating enzyme in activated immune cells including microglia , we then examined whether naloxone directly targeted NOX2 and suppressed superoxide production in a cell-free system. Since it is difficult to generate a sufficient amount of cell membrane from primary microglia for this assay, we used blood neutrophils, which contain a high abundance of NOX2. Neutrophils were first treated with PMA, a widely used agent for superoxide production by stimulating NOX2; and then cell membranes were isolated and used for the measurement of superoxide production by adding NADPH, ferricytochrome c, and FAD. As shown in Figure 1C, both (-) and (+)-naloxone (10 μM) inhibited NADPH-dependent superoxide generation by PMA-stimulated neutrophil membranes. This result indicates a direct inhibitory effect of naloxone on NOX2.
3H-Naloxone binding is increased in the presence of the gp91phoxmembrane subunit
The gp91phoxis the catalytic subunit of NOX2 enzyme and mainly locates in the plasma membrane of neutrophils, microglia and macrophages. We hypothesized that naloxone might inhibit the LPS-induced increase in superoxide production by directly binding to the gp91phox. To test this possibility, ligand binding assays were performed using various cell types containing or lacking the gp91phox. Initially, BV2 cells, a murine microglia cell line, were used for competition studies. Binding of 3H labeled (-)-naloxone was displaced with a wide range of both cold (-) and (+)-naloxone (0.01 μM to 100 μM). As shown in Figure 2, both (-) and (+)-naloxone inhibited 3H-naloxone binding to BV2 microglia in a dose-dependent manner with an IC50 of 2.73 and 1.57 μM, respectively. These IC50 values for binding affinity are similar to the IC50 values for inhibiting LPS-induced superoxide production (Figure 1A: 1.92 and 2.56 μM), indicating a well-correlated event between the binding and the inhibition of NOX2. Since the binding affinity of (-)-naloxone toward opioid receptors is approximately 10,000 times higher than that of (+)-naloxone, the equi-potency of these two naloxone isomers in binding to BV2 microglia represents a novel opioid receptor-independent binding site.
To investigate whether naloxone could bind to the gp91phox subunit, we performed binding experiments by using neutrophils, which contain the highest level of gp91phox among phagocytes, prepared from gp91phox-/- and gp91phox+/+ (WT) mice. Whole cells or cell membrane fractions (cell free system) prepared from neutrophils were incubated with 3H-naloxone for 2 hour at 4°C. The binding capacity of naloxone to the gp91phox in WT neutrophils was determined by comparing it with that of gp91phox-/- neutrophils. Deficiency in gp91phox significantly decreased naloxone binding to neutrophils in both whole cell and cell membranes (Figure 3A). Similar experiments were performed using COS-7 cells stably expressed with the gp91phox and p22phox (COS-7-gp91phox-p22phox) or in combination with p47phox and p67phox (COS-NOX2) (Detailed transfection results are shown in Figure 4). The reason for the co-transfection of gp91phox and p22phox is that p22phox facilitates stable expression of gp91phox in the plasma membrane of COS7 cells . As shown in Figure 3B, 3H-naloxone binding capacity was much higher in gp91phox-transfected cells compared with empty vector-transfected COS-7 cells, which do not express gp91phox. Transient expression of gp91phox in HEK293 cells was also found to elevate naloxone binding (Figure 3B). It should be noted that the decrease of naloxone binding in gp91phox deficiency neutrophils was about 40% of total binding, the remaining 50% to 60% was attributed to nonspecific binding. This result is consistent with a previous report by Simpkins et al. showing about 60% nonspecific 3H-naloxone binding in human neutrophils . The presence of opioid receptors in phagocytes  and the low binding affinity of 3H-naloxone to the gp91phox subunit may explain the relatively high non-specific binding in ours and Simpkins' report. To insure the specificity of naloxone binding to gp91phox, we have further performed an immunoprecipitation study using anti-gp91phox antibody. A much higher increase (2.5 fold) in the binding of 3H-naloxone to immunoprecipitated COS7-gp91phox-p22phox membrane proteins was observed compared with immunoprecipitated COS-7 WT membrane proteins with no gp91phox (Figure 3C). Together, these binding results imply that naloxone could directly interact with the gp91phox-p22phox complex, and specially, subunit gp91phox.
NOX2 activation by PMA enhances the binding capacity of naloxone
The above-described naloxone binding studies were performed while NOX2 was in the resting stage. Additional experiments were performed to determine the binding capacity of naloxone while the enzyme was in the activated stage. For this purpose, PMA, a widely used compound for the activation of NOX2, was used. It is known that through the activation of PKC, PMA induces the translocation of the cytosolic subunits to the membrane and increases the production of superoxide in phagocytes. In the present study, we examined the binding capacity of naloxone to gp91phox after PMA treatment in COS-7-NOX2 cells. PMA treatment activated NOX2 by inducing the membrane translocation of cytosolic subunits (Figure 5). As shown in Figure 6, naloxone binding was elevated in PMA-treated COS-7-NOX2 cells compared to the vehicle treatment. PMA treatment had no influence on background binding of naloxone to COS-7 cells. These results suggest that changes in the conformation resulted from the binding of cytosolic subunits to the gp91phox, rendering NOX2 in the activated stage, may enhance the binding of naloxone.
Diphenyliodonium (DPI), a NOX2 inhibitor, reduces 3H-naloxone binding
It was reported that DPI binds to the redox core, such as photoreduced flavin or heme of the gp91phox, and subsequently prevents electron transport [22, 23]. Our results showed that DPI pretreatment reduced the binding of naloxone in WT neutrophils and the capacity of naloxone binding became the same between WT controls and the gp91phox-/- group (Figure 7A). DPI failed to attenuate 3H-naloxone binding to gp91phox-/- neutrophils. Similar results were also demonstrated in COS-7 cells stably expressed with the gp91phox-p22phox complex with or without the cytosolic subunits. The increases in 3H-naloxone binding in transfected cells were not observed in DPI-treated groups (Figure 7B). These data suggest a possible competition between naloxone and DPI. However, it is important to note that it is not clear from this study whether naloxone and DPI compete for the same binding site. It is possible that naloxone and DPI have different binding sites on gp91phox. Conformational changes of gp91phox after DPI binding may reduce naloxone's binding to gp91phox. It remains to be determined whether naloxone binds to heme, the C-terminal flavin domain, or any specific domain of gp91phox.
Pre-treatment of naloxone inhibits translocation of the NOX2 p47phox cytosolic subunit to membrane
NOX2 consists of the membrane catalytic subunits gp91phox and p22phox, together with several cytosolic regulatory subunits, p47phox, p40phox, p67phox and a small GTPase RAC . It has previously been shown that activation of the NOX2 enzyme requires that the cytosolic component p47phox be phosphorylated and subsequently translocated along with the p67phox component to the plasma membrane, where they associate with the gp91phox component to assemble into an active enzyme complex. To determine how naloxone inhibited NOX2 activity after binding to the gp91phox, we investigated the membrane translocation of p47phox by determining the cytosolic and membrane levels of p47phox. BV2 microglia were pretreated with vehicle or naloxone for 30 minutes, followed by LPS treatment for 15 minutes. Western blot analyses showed an increase in p47phox levels in the membrane fraction of BV2 microglia 10 minutes after LPS exposure, which was prevented by naloxone pretreatment (Figure 8). At the same time, the decrease of p47phox levels in the cytosolic fraction of BV2 microglia induced by LPS was also attenuated by naloxone. Together, these results suggest that binding of naloxone to the gp91phox may change the conformation of this membrane component, preventing the membrane translocation of cytosolic subunits of NOX2.
Post-treatment of naloxone is still capable of inhibiting pre-existing increased binding of p47phox in membrane elicited by pre-treatment of LPS
Results from the previous figure (Figure 8) indicate that pre-treatment with naloxone inhibits LPS-induced superoxide and that this is associated with reduction of translocation of cytosolic subunits to the plasma membrane. It is interesting to note that our previous report indicated that post-treatment with naloxone is also partially effective in preventing LPS-induced DA neuron damage . To explain this post-treatment phenomenon, we hypothesize that naloxone is also capable of attenuating NOX2 activity by reducing the amount of membrane-bound p47 and other cytosolic subunits produced by LPS. For this purpose, an experiment using a post-treatment of naloxone paradigm was conducted by preparing membrane fractions from BV2 microglia, which were pre-treated with LPS or vehicle for 15 minutes, and then incubated with or without naloxone. As shown in Figure 9, pre-treatment of LPS activated NOX2 enzyme by inducing translocation to the membrane of the cytosolic subunit p47phox. After 30 minutes of naloxone post-treatment, the levels of p47phox in the membrane significantly decreased, which suggests naloxone counteracted the membrane translocation of the cytosolic subunit p47phox. These results suggest that naloxone can inhibit the activated NOX2 enzyme by reducing the binding of cytosolic subunits to the membrane.
In this study, we demonstrate a non-opioid novel naloxone binding site, which is critical in mediating its anti-inflammatory actions. The salient features of our findings are: 1) both (-) and (+)-naloxone inhibit LPS- and PMA-induced superoxide production in neuron-glia cultures and neutrophil membranes, respectively. In contrast, both isomers failed to reduce superoxide produced by the xanthine/xanthine oxidase system, indicating that the inhibition of superoxide production by naloxone is not due to its superoxide free radical scavenging effect; 2) specific binding of 3H-naloxone to gp91phox, the membrane subunit of NOX2, was demonstrated by an immunoprecipitation study using gp91phox antibody, and the binding affinity was further enhanced after NOX2 was activated; 3) Pre-treatment with naloxone prevented the translocation of cytosolic subunits of NOX2 to the plasma membrane. In addition, post-treatment with naloxone of activated NOX2 reduced the binding of cytosolic subunits with plasma membrane. Taken together, this study provides strong evidence demonstrating that naloxone directly binds to gp91phox. Decreased NOX2-generated superoxide production was critical in mediating the anti-inflammatory and neuroprotective effects of naloxone (Figure 10).
Several reports have documented that naloxone inhibits superoxide production from microglia and neutrophils in an opioid receptor-independent manner [6, 18, 26]; however, the underlying mechanism remains unclear. Since naloxone contains a phenolic hydroxyl group, we first assessed the possibility that the reduction in superoxide production is due to its free radical scavenging effect. This possibility was ruled out since both (-)- and (+)-naloxone failed to reduce levels of superoxide produced by the xanthine/xanthine oxidase system (Figure 1). This finding led us to propose the possibility that naloxone acts by interfering with upstream events of superoxide generation. Using different types of phagocytes deficient in the gp91phox subunit or non-phagocytes transfected with different subunits of NOX2, we provide clear evidence indicating a direct binding of naloxone to the membrane subunit, gp91phox (Figure 3). 3H-Naloxone binding capacity was decreased in neutrophils deficient in gp91phox. In contrast, 3H-naloxone binding in COS-7 and HEK293 cells transfected with gp91phox was elevated compared with vehicle-transfected controls. After enrichment of gp91phox protein from COS-7-gp91phox-p22phox cell membranes by immunoprecipitation using anti-gp91phox antibody, the radiolabeled naloxone binding showed greater differences in the presence and absence of gp91phox (Figure 3C). Overall, our data show a good correlation between the binding affinity of naloxone to the gp91phox and its inhibition of LPS-induced superoxide production with similar IC50 values (around 2 μM, Figures 1A & 2).
It is important to note that the micromolar IC50 values reported here are much higher than the reported binding affinity of 3H-naloxone to conventional opioid receptors (in nanomolar concentrations) . The question is whether these concentrations are clinically relevant for the anti-inflammatory and neuroprotective effects of naloxone. Earlier reports indicated that micromolar concentrations can be reached both in serum and brains after naloxone treatment. Tepperman et al. showed that the peak plasma naloxone concentrations in rats were 2.1 and 17 μM after a single subcutaneous injection of naloxone with doses of 1.0 or 10 mg/kg, respectively. Furthermore, it has been reported that brain levels of naloxone are six to seven times higher than that in plasma , which might be attributed to involvement of a pH-dependent and saturable influx transport system in the blood-brain barrier transport of naloxone . Our previous report showed that systemic infusion of naloxone (0.4 to 4 mg/kg/day for two weeks with a mini-osmotic pump) dose-dependently attenuated LPS-induced nigral dopaminergic neuron loss in rats , and this further supports this contention.
Although we have identified microglial gp91phox as a novel binding site in mediating the anti-inflammatory effect of naloxone, the underlying mechanism of how the binding affects subsequent NOX2 activation remains to be studied. Several studies have reported that naloxone could directly alter membrane characteristics. In a hemorrhagic shock rodent model, Curtis and Lefer demonstrated that naloxone increases circulating lysosomal hydrolase activities and suggested that this action results from stabilization of lysosomal membranes . Similarly, inhibition of Na+ and K+ currents in myelinated nerve fibers of sciatic nerve and membrane potential of some cells have also been reported [31, 32]. Thus, we speculated that binding of naloxone to gp91phox might change the conformation of the protein complex and subsequently decrease the affinity of binding of the cytosolic subunits (p47phox, p67phox). One common approach to determine the binding affinity between the cytosolic and membrane subunits of NOX2 is the measurement of translocation of cytosolic subunits to the membrane. Since it is known that the p67phox is the subunit that directly binds to the gp91phox protein, it would be desirable to measure the translocation of this subunit. However, the lack of suitable antibodies against p67phox prevented us from performing this experiment. For this reason, an antibody against p47phox, which is also bound to the membrane through formation of a complex with p67phox, was used.
Our speculation is supported by the finding that naloxone pre-treatment reduces the translocation of p47phox (Figure 8). It is of interest to note that post-treatment with naloxone was also capable of reducing the LPS-induced increase in the amount of phosphorylatd p47phox in the cell membrane fraction (Figure 9). These results suggest that binding of naloxone to activated NOX2 may alter the conformation of gp91phox and subsequently decrease binding affinity between cytosolic subunits and the membrane subunit. Although we do not yet have evidence showing actual conformational change of gp91phox after naloxone binding, this finding serves to explain why post-treatment of naloxone is still effective in anti-inflammation and neuroprotection. That conformational changes can also alter the binding capacity of 3H-naloxone binding is further illustrated by the finding that binding of 3H-naloxone in NOX2-transfected COS-7 cells was greatly enhanced after NOX2 was activated by PMA (Figure 6). Taken together, our data strongly suggest that naloxone alters binding affinity between gp91phox and the cytosolic subunits.
The non-opioid actions of naloxone have recently received wide attention mainly due to its potential new indications for a variety of diseases. One of the major advances in this research area is the recognition of an anti-nociceptive action of naloxone. Glial activation has been demonstrated to oppose opioid analgesia and enhance opioid tolerance, dependence, reward and respiratory depression by upregulating the production of proinflammatory cytokines (TNFα, IL-1), pain-relevant neurotransmitters from sensory afferent terminals and the number and/or conductivity of AMPA and NMDA glutamate receptors [33–35]. Naloxone, including both (-) and (+) isomers, has been reported to potentiate morphine analgesia equally by blocking morphine-induced glial activation and consequent increases in anti-analgesic proinflammatory cytokines [8, 9, 36]. Similarly, hyperalgesia induced by morphine-3-glucoronide (M3G), a major morphine metabolite that has little or no affinity for opioid receptors, is also blocked or reversed by (-) and (+)-naloxone . TLR4 was recently recognized to mediate such effects [38–40]. Experiments are underway in our laboratory to determine whether the anti-inflammatory effect of naloxone mentioned above is due to a direct action on the TLR-4 receptor or is indirect through the inhibition of NOX2 inhibition. We performed a radioligand binding assay with microglia prepared from TLR-4-deficient mice. Preliminary results failed to show a decrease in 3H-naloxone binding in TLR-4-deficient microglia compared with wild type controls (Wang et al., preliminary observations). Thus, the inhibitory effect shown on the TLR-4 receptor is likely due to an indirect effect through binding to NOX2. In fact, we have previously reported that naloxone inhibits LPS-induced production of proinflammatory factors, such as TNFα and prostaglandins, through inhibition of NOX2-generated superoxide release . Regardless of the site of action, the potential interactions between TLR-4 and NOX2 can be a critical pathway governing innate immunity and warrant further study.
Naloxone belongs to a class of compounds termed as morphinans, with chemical structures similar to morphine. We have previously reported that a large number of morphinan analogs, such as (-) and (+) morphine , dextromethorphan [43, 44], 3-hydroxymorphinan [45, 46] and sinomenine  display potent anti-inflammatory and neuroprotective effects similar to that of naloxone. These morphinan analogs have recently received a great deal of attention due to their new therapeutic implications for a variety of diseases, ranging from neuroprotection, anti-nociception, and bipolar depression to drug addiction. Using both invivo and primary neuron-glia cell cultures derived from gp91phox-/- mice, we have previously reported that NOX2 is critical in mediating this morphinans-afforded neuroprotection similar to that of naloxone. Further, our preliminary data show that dextromethorphan is able to bind similarly to what we describe for naloxone in this paper, suggesting that gp91phox might be a common binding site for the above-mentioned morphinans in their anti-inflammatory property (unpublished data).
In summary, we provided strong evidence indicating that NOX2 is a non-opioid novel binding site for naloxone, which is critical in mediating its inhibitory effect on microglia overactivation and superoxide production. Although the new implications elicited by the mechanisms of morphinan analogs remain to be studied, the identification of this novel non-opioid binding site mediating the important anti-inflammatory action of naloxone should provide new insights into further understanding the mechanism of action of other morphinan analogs and help better design new drugs targeting this important free radical-producing enzyme.
amyotrophic lateral sclerosis
ethylene glycol tetraacetic acid
fetal bovine serum
hank's buffered salt solution
interleukin 1 β
minimum essential media
phorbol myristate acetate
sodium dodecyl sulfate polyacrylamide gel electrophoresis
Toll-like receptor 4
tumor necrosis factor α
water soluble tetrazolium salt 1.
This research was supported by the Intramural Research Program of the National Institutes of Health/National Institute of Environmental Health Sciences. We thank Dr. Saurabh Chatterjee and Baozhong Zhao at the National Institute of Environmental Health Sciences and Esteban Oyarzabal at University of North Carolina, Chapel Hill, for their helpful suggestions in editing this article.
Neuropharmacology Section (Q.S.W., H.Z., H.M.G., S.H.C., C.H.C., B.W., J.S.H.), Laboratory of Toxicology and Pharmacology, National Institute of Environmental Health Sciences
Gao HM, Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.Trends Immunol 2008, 29:357–365.PubMedView Article
Nelson PT, Soma LA, Lavi E: Microglia in diseases of the central nervous system.Ann Med 2002, 34:491–500.PubMedView Article
Liu B, Du L, Hong JS: Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation.J Pharmacol Exp Ther 2000, 293:607–617.PubMed
Liu B, Du L, Kong LY, Hudson PM, Wilson BC, Chang RC, Abel HH, Hong JS: Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia co-cultures.Neuroscience 2000, 97:749–756.PubMedView Article
Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, Wu GC, Cao XD, Hong JS: Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide.J Pharmacol Exp Ther 2000, 295:125–132.PubMed
Liu Y, Qin L, Wilson BC, An L, Hong JS, Liu B: Inhibition by naloxone stereoisomers of beta-amyloid peptide (1–42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons.J Pharmacol Exp Ther 2002, 302:1212–1219.PubMedView Article
Qin L, Block ML, Liu Y, Bienstock RJ, Pei Z, Zhang W, Wu X, Wilson B, Burka T, Hong JS: Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress.FASEB J 2005, 19:550–557.PubMedView Article
Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, Patel SJ, Crysdale NY, Harrison JA, Maier SF, et al.: Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).Eur J Neurosci 2008, 28:20–29.PubMedView Article
Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR: Evidence that opioids may have toll-like receptor 4 and MD-2 effects.Brain Behav Immun 2010, 24:83–95.PubMedView Article
Wang HY, Burns LH: Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine.PLoS One 2009, 4:e4282.PubMedView Article
Yang L, Li F, Ge W, Mi C, Wang R, Sun R: Protective effects of naloxone in two-hit seizure model.Epilepsia 2010, 51:344–353.PubMedView Article
Liu SL, Li YH, Shi GY, Chen YH, Huang CW, Hong JS, Wu HL: A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice.J Am Coll Cardiol 2006, 48:1871–1879.PubMedView Article
Gao HM, Hong JS, Zhang W, Liu B: Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons.J Neurosci 2002, 22:782–790.PubMed
Luo Y, Dorf ME: Isolation of mouse neutrophils.Curr Protoc Immunol 2001,3(3):20.PubMed
Herren T, Burke TA, Jardi M, Felez J, Plow EF: Regulation of plasminogen binding to neutrophils.Blood 2001, 97:1070–1078.PubMedView Article
Zhou H, Zhang F, Chen SH, Zhang D, Wilson B, Hong JS, Gao HM: Rotenone activates phagocyte NADPH oxidase by binding to its membrane subunit gp91(phox).Free Radic BiolMed 2012, 52:303–313.View Article
Qian L, Wei SJ, Zhang D, Hu X, Xu Z, Wilson B, El-Benna J, Hong JS, Flood PM: Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia.J Immunol 2008, 181:660–668.PubMed
Simpkins CO, Alailima ST, Tate EA: Inhibition by naloxone of neutrophil superoxide release: a potentially useful antiinflammatory effect.Circ Shock 1986, 20:181–191.PubMed
Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.Physiol Rev 2007, 87:245–313.PubMedView Article
Yu L, Zhen L, Dinauer MC: Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits.J Biol Chem 1997, 272:27288–27294.PubMedView Article
Caldiroli E, Leoni O, Cattaneo S, Rasini E, Marino V, Tosetto C, Mazzone A, Fietta AM, Lecchini S, Frigo GM: Neutrophil function and opioid receptor expression on leucocytes during chronic naltrexone treatment in humans.Pharmacol Res 1999, 40:153–158.PubMedView Article
Doussiere J, Gaillard J, Vignais PV: The heme component of the neutrophil NADPH oxidase complex is a target for aryliodonium compounds.Biochemistry 1999, 38:3694–3703.PubMedView Article
O'Donnell BV, Tew DG, Jones OT, England PJ: Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase.Biochem J 1993, 290:41–49.PubMed
Lambeth JD: NOX enzymes and the biology of reactive oxygen.Nat Rev Immunol 2004, 4:181–189.PubMedView Article
Liu B, Hong JS: Neuroprotective effect of naloxone in inflammation-mediated dopaminergic neurodegeneration. Dissociation from the involvement of opioid receptors.Methods Mol Med 2003, 79:43–54.PubMed
Simpkins CO, Ives N, Tate E, Johnson M: Naloxone inhibits superoxide release from human neutrophils.Life Sci 1985, 37:1381–1386.PubMedView Article
Price M, Gistrak MA, Itzhak Y, Hahn EF, Pasternak GW: Receptor binding of [3H]naloxone benzoylhydrazone: a reversible kappa and slowly dissociable mu opiate.Mol Pharmacol 1989, 35:67–74.PubMed
Tepperman FS, Hirst M, Smith P: Brain and serum levels of naloxone following peripheral administration.Life Sci 1983, 33:1091–1096.PubMedView Article
Suzuki T, Ohmuro A, Miyata M, Furuishi T, Hidaka S, Kugawa F, Fukami T, Tomono K: Involvement of an influx transporter in the blood-brain barrier transport of naloxone.Biopharm Drug Dispos 2010, 31:243–252.PubMed
Curtis MT, Lefer AM: Protective actions of naloxone in hemorrhagic shock.Am J Physiol 1980, 239:H416-H421.PubMed
Carratu MR, Mitolo-Chieppa D: Inhibition of ionic currents in frog node of Ranvier treated with naloxone.Br J Pharmacol 1982, 77:115–119.PubMed
Gutierrez R: Effects of naloxone on membrane potential of identified neurons of Helix aspersa.Comp Biochem Physiol C 1992, 101:425–431.PubMedView Article
Watkins LR, Hutchinson MR, Johnston IN, Maier SF: Glia: novel counter-regulators of opioid analgesia.Trends Neurosci 2005, 28:661–669.PubMedView Article
Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, Langer S, Martin D, Green P, Fleshner M, Leinwand L, Maier SF, Watkins LR: A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine.J Neurosci 2004, 24:7353–7365.PubMedView Article
Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR: Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward.ScientificWorldJournal 2007, 7:98–111.PubMedView Article
Lewis SS, Hutchinson MR, Rezvani N, Loram LC, Zhang Y, Maier SF, Rice KC, Watkins LR: Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta.Neuroscience 2010, 165:569–583.PubMedView Article
Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR: Evidence that opioids may have toll-like receptor 4 and MD-2 effects.Brain, Behav Immun 2010, 24:83–95.View Article
Liu L, Coller JK, Watkins LR, Somogyi AA, Hutchinson MR: Naloxone-precipitated morphine withdrawal behavior and brain IL-1beta expression: comparison of different mouse strains.Brain, Behav Immun 2011, 25:1223–1232.View Article
Watkins LR, Hutchinson MR, Rice KC, Maier SF: The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.Trends in pharmacological sciences 2009, 30:581–591.PubMedView Article
Qin L, Block ML, Liu Y, Bienstock RJ, Pei Z, Zhang W, Wu X, Wilson B, Burka T, Hong JS: Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress.FASEB J 2005, 19:550–557.PubMedView Article
Qian L, Tan KS, Wei SJ, Wu HM, Xu Z, Wilson B, Lu RB, Hong JS, Flood PM: Microglia-mediated neurotoxicity is inhibited by morphine through an opioid receptor-independent reduction of NADPH oxidase activity.J Immunol 2007, 179:1198–1209.PubMed
Li G, Cui G, Tzeng NS, Wei SJ, Wang T, Block ML, Hong JS: Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage.FASEB J 2005, 19:489–496.PubMedView Article
Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Hong JS, Liu B: Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.FASEB J 2004, 18:589–591.PubMed
Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, Wilson B, Liu B, Kim HC, Hong JS: 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.FASEB J 2005, 19:395–397.PubMed
Zhang W, Shin EJ, Wang T, Lee PH, Pang H, Wie MB, Kim WK, Kim SJ, Huang WH, Wang Y, Zhang W, Hong JS, Kim HC: 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.FASEB J 2006, 20:2496–2511.PubMedView Article
Qian L, Xu Z, Zhang W, Wilson B, Hong JS, Flood PM: Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase.J Neuroinflammation 2007, 4:23.PubMedView Article
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.